Search results for "Staging."

showing 10 items of 715 documents

Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.

2014

Purpose Bevacizumab plus fluoropyrimidine-based chemotherapy is standard treatment for first-line and second-line metastatic colorectal cancer (mCRC). However, to date, there is no current biomarker predictive for the benefit of bevacizumab use for these patients. Preclinical data suggest that the presence of the primary tumor could be involved in less efficient antitumor activity of antiangiogenic agents, but no clinical data currently support this hypothesis. Methods We performed a retrospective analysis of factors associated with overall survival (OS) in a study cohort of 409 mCRC patients. Univariate and multivariate Cox proportional hazard regression models were used to assess the infl…

OncologyAdultMalemedicine.medical_specialtyBevacizumabOrganoplatinum CompoundsColorectal cancerAdenocarcinomaAntibodies Monoclonal HumanizedIrinotecanDeoxycytidineCapecitabineSurgical oncologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesNeoplasm MetastasisSurvival rateCapecitabineAgedNeoplasm StagingRetrospective StudiesAged 80 and overColorectal Cancerbusiness.industryMiddle Agedmedicine.diseasePrognosisPrimary tumorCombined Modality TherapyBevacizumabOxaliplatinSurvival RateOncologyAdenocarcinomaBiomarker (medicine)SurgeryCamptothecinFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drugFollow-Up StudiesAnnals of surgical oncology
researchProduct

Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial

2020

International audience; Background: Adjuvant treatment for stage II colon cancer remains debated. Finding a tool to select patients at risk for disease recurrence may help the clinical decision. Circulating tumor DNA (ctDNA) has been reported recently as a potential predictive marker for disease recurrence. We thus aim to test its ability to better select stage II colon cancer patients for adjuvant therapy.Methods: This national, phase III trial (NCT00002019-000935-15) conducted in more than 100 centers in France, plans to screen around 2640 patients in order to randomize (2:1; minimization method) 198 ctDNA positive patients. Patients aged 18 to 75 years with ECOG performance status ≤1 wit…

OncologyAdultMalemedicine.medical_specialtyMethylated biomarker.AdolescentColorectal cancermedicine.medical_treatment[SDV]Life Sciences [q-bio]LeucovorinRectumDisease-Free Survival03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicinemedicineAdjuvant therapyBiomarkers TumorHumansAdjuvantAgedNeoplasm StagingCirculating tumor DNAPredictive markerHepatologybusiness.industryGastroenterologyMiddle Agedmedicine.disease3. Good healthOxaliplatinColon cancerOxaliplatin[SDV] Life Sciences [q-bio]medicine.anatomical_structureTreatment OutcomeChemotherapy Adjuvant030220 oncology & carcinogenesisColonic NeoplasmsAdenocarcinoma030211 gastroenterology & hepatologyFemaleFluorouracilFranceBolus (digestion)businessAdjuvantmedicine.drug
researchProduct

Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model

2008

Background Despite the prophylactic use of allopurinol, tumor lysis syndrome (TLS)- related morbidity and mortality still occur in a number of patients with acute myeloid leukemia (AML).The aim of this study was: (i) to analyze the incidence and outcome of TLS in a large series of patients with AML receiving hyperhydration and allopurinol, (ii) to identify risk factors for TLS, and (iii) to develop a prognostic scoring system for estimating individual risk of TLS. Design and Methods The study included 772 adult patients with AML receiving induction chemotherapy between 1980 and 2002. TLS was divided into laboratory TLS (LTLS) or clinical TLS (CTLS).The population study was randomly divided …

OncologyAdultMalemedicine.medical_specialtyMyeloidAdolescentAntineoplastic Agentsacute myeloid leukemiapredictive modelRisk FactorsInternal medicinemedicineRasburicaseHumansrisk factorsRisk factorAgedNeoplasm StagingAged 80 and overHematologybusiness.industryMyeloid leukemiaInduction chemotherapyHematologyMiddle Agedmedicine.diseasePrognosisTumor lysis syndromeLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureTreatment OutcomeImmunologyincidenceFemaletumor lysis syndromebusinessTumor Lysis Syndromemedicine.drug
researchProduct

The prevalence of human papilloma virus (HPV) infections in oral squamous cell carcinomas: a retrospective analysis of 88 patients and literature ove…

2014

In addition to tobacco and alcohol consumption, the two main risk factors for oral squamous cell carcinoma (OSCC), recent studies have revealed infections with human papilloma virus (HPV) as an additional risk factor for OSCC development. In the field of head and neck malignancies, the prevalence of HPV infections in oropharyngeal cancer (OC) ranges in different studies up to 84%. While HPV infection is discussed as an independent risk factor in this region, its distinguished role in carcinogenesis of tumours localized to the oral cavity remains still uncertain. In this study, we analysed the HPV status in 88 consecutive patients with OSCCs localized anterior of the palatoglossal arch who w…

OncologyAdultMalemedicine.medical_specialtyPathologyAlcohol DrinkingCarcinogenesisCellAlphapapillomavirusmedicine.disease_causePalatine tonsilYoung AdultSex FactorsInternal medicineGermanyPrevalenceMedicineHumansRisk factorAgedNeoplasm StagingRetrospective StudiesHuman papilloma virusAged 80 and overHuman papillomavirus 16Human papillomavirus 18business.industryPapillomavirus InfectionsSmokingHPV infectionAge Factorsvirus diseasesCancerMiddle Agedmedicine.diseasestomatognathic diseasesOropharyngeal Neoplasmsmedicine.anatomical_structureOtorhinolaryngologyOral and maxillofacial surgeryCarcinoma Squamous CellSurgeryFemaleMouth NeoplasmsOral SurgerybusinessCarcinogenesisJournal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
researchProduct

Hepatocellular carcinoma: comparison of two different periods at the same center.

2010

Aims: To analyze the main etiological factors and some clinical characteristics of patients with HCC at diagnosis and to compare them with those we described ten years ago. Methods: 179 patients were included in Group 1, while 132 patients were included in Group 2. For all patients age, sex, serum markers of hepatitis B and C viruses, alcohol consumption, serum alpha feto-protein (AFP) levels and the main liver function parameters at HCC diagnosis were recorded. Results: Mean age was 66.0 years for Group 1 and 69.0 for Group 2 (P=0.005). HCV was responsible for 80.3% of HCC cases in Group 2 versus 72% in Group 1 (P=0.005). HBV alone and co-infection of HCV+HBV decreased, but not significant…

OncologyAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaCarcinoma HepatocellularTime FactorsAlcohol DrinkingAlpha (ethology)Gastroenterologyhepatocellular carcinoma Etiology Staging DiagnosisLiver diseaseLiver Function TestsInternal medicineInternal MedicinemedicineHumansAgedNeoplasm StagingAged 80 and overmedicine.diagnostic_testbusiness.industryLiver NeoplasmsHepatitis CHepatitis BMiddle Agedmedicine.diseaseHepatitis BHepatitis Cdigestive system diseasesItalyHepatocellular carcinomaEtiologyFemaleLiver functionalpha-FetoproteinsLiver function testsbusinessEuropean journal of internal medicine
researchProduct

Effect of c-Met expression on survival in head and neck squamous cell carcinoma

2005

The proto-oncogene c-Met has been suggested to be associated with progression of squamous cell carcinoma of the head and neck. The aims of the present study were to assess the prevalence of c-Met expression in oral squamous cell carcinoma (OSCC) and to verify whether c-Met can be considered a marker of prognosis in these patients. In a retrospective study, a cohort of 84 OSCC patients was investigated for c-Met expression and its cellular localization by immunohistochemistry. After grouping for c-Met expression, OSCC patients were statistically analyzed for the variables age, gender, histological grading, tumor node metastasis, staging and overall survival rate. Univariate and multivariate …

OncologyAdultMalemedicine.medical_specialtyc-Met; Cox regression analysis; Oral squamous cell carcinoma;C-MetAdolescentcox regression analysisProto-Oncogene Maschemistry.chemical_compoundInternal medicinemedicineBiomarkers TumorHumansBasal cellHead and neckc-MetNeoplasm Stagingbusiness.industryMouth MucosaGeneral MedicineMiddle AgedProto-Oncogene Proteins c-metmedicine.diseasePrognosisHead and neck squamous-cell carcinomaImmunohistochemistryUp-Regulationoral squamous cell carcinomastomatognathic diseaseschemistryCarcinoma Squamous CellFemaleMouth Neoplasmsbusiness
researchProduct

Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No …

2002

BACKGROUND: To determine whether patients with high-risk metastatic breast cancer draw benefit from combination chemotherapy as first-line treatment. PATIENTS AND METHODS: A total of 260 women with measurable metastatic breast cancer fulfilling high-risk criteria, previously untreated with chemotherapy for their metastatic disease, were randomized to receive either mitoxantrone 12 mg/m(2) or the combination of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2) and cyclophosphamide 500 mg/m(2) (FEC) every 3 weeks. Treatment was continued until complete remission plus two cycles, or until disease progression. In the case of partial remission or stable disease, treatment was stopped after 12 cycl…

OncologyAdultmedicine.medical_specialtyLung NeoplasmsCyclophosphamidemedicine.medical_treatmentBone NeoplasmsBreast NeoplasmsRisk AssessmentSensitivity and SpecificityDisease-Free SurvivalStatistics NonparametricInternal medicineGermanyAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideAgedEpirubicinNeoplasm StagingProbabilityProportional Hazards ModelsChemotherapyMitoxantronePerformance statusbusiness.industryBiopsy NeedleLiver NeoplasmsCombination chemotherapyHematologyMiddle Agedmedicine.diseaseMetastatic breast cancerSurvival AnalysisSurgeryLogistic ModelsTreatment OutcomeOncologyQuality of LifeVindesineFemaleFluorouracilMitoxantronebusinessmedicine.drugEpirubicinAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Breast cancer subtypes can be determinant in the decision making process to avoid surgical axillary staging: A retrospective cohort study.

2015

Abstract Introduction The need for performing axillary lymph-node dissection in early breast cancer when the sentinel lymph node (SLN) is positive has been questioned in recent years. The purpose of this study was to identify a low-risk subgroup of early breast cancer patients in whom surgical axillary staging could be avoided, and to assess the probability of having a positive lymph-node (LN). Methods We evaluated the cohort of 612 consecutive women affected by early breast cancer. We considered age, tumor size, histological grade, vascular invasion, lymphatic invasion and cancer subtype (Luminal A, Luminal B HER-2+, Luminal B HER-2−, HER-2+, and Triple Negative) as variables for univariat…

OncologyAdultmedicine.medical_specialtyLymphovascular invasionReceptor ErbB-2Sentinel lymph nodeClinical Decision-Makingbreast cancer axillary surgery sentinel lymph node biopsy adjuvant treatment biological prognostic factors.Breast NeoplasmsTriple Negative Breast NeoplasmsCohort StudiesBreast cancerInternal medicineMedicineHumansNeoplasm InvasivenessSettore SECS-S/05 - Statistica SocialeLymph nodeAgedNeoplasm StagingRetrospective StudiesGynecologyAged 80 and overbusiness.industrySentinel Lymph Node BiopsyAge FactorsCancerRetrospective cohort studyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseSettore MED/18 - Chirurgia GeneraleExact testmedicine.anatomical_structureLymphatic MetastasisAxillaLymph Node ExcisionSurgeryFemalebusinessInternational journal of surgery (London, England)
researchProduct

Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma.

2010

Abstract Objective The excision repair cross-complementation group 1 (ERCC1) expression is a predictor of survival after surgical treatment for several malignancies. Its overexpression has been reported as a marker of platinum resistance in lung cancer. However, the relevance of ERCC1 expression in ovarian cancer (OC) is the subject of controversy, both as a predictive parameter for platinum resistance and because of its association with poor prognosis. Therefore, we performed a retrospective study investigating ERCC1 expression and its correlation with patients' survival in OC. Methods We analyzed the ERCC1 protein expression using four different ERCC1 antibodies (clone 8F1) with different…

OncologyAdultmedicine.medical_specialtyNeoplasm Residualmedicine.medical_treatmentERCC1 Protein ExpressionPredictive Value of TestsInternal medicineOvarian carcinomamedicineHumansLung cancerSurvival rateAgedNeoplasm StagingRetrospective StudiesAged 80 and overOvarian NeoplasmsChemotherapybusiness.industryAge FactorsObstetrics and GynecologyMiddle Agedmedicine.diseaseEndonucleasesImmunohistochemistryCystadenocarcinoma SerousDNA-Binding ProteinsSerous fluidOncologyFemaleERCC1businessOvarian cancerGynecologic oncology
researchProduct

Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of th…

2000

We determined prospectively the incidence of chromosomal abnormalities in patients with high-risk breast cancer (HRBC) after high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT), and correlated the cytogenetic abnormalities with the development of post-transplant myelodysplastic syndrome or acute myeloid leukemia (MDS/AML). From 1990 to 1999, 229 women with HRBC underwent ASCT. Cytogenetic analysis of bone marrow (BM) cells was performed 12–59 months after ASCT in 60 consecutive women uniformly treated with six courses of FAC/FEC followed by HDCT and ASCT. With a median follow-up of 36 months after ASCT, there were no cases of MDS/AML among the 229 patients. In the …

OncologyAdultmedicine.medical_specialtyPathologyPopulationAneuploidyBreast NeoplasmsTransplantation AutologousBreast cancerAutologous stem-cell transplantationBone MarrowPredictive Value of Testshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsAdjuvant therapyMedicineHumanseducationCyclophosphamideEpirubicinNeoplasm StagingChromosome AberrationsTransplantationeducation.field_of_studyLeukemiabusiness.industryHematopoietic Stem Cell TransplantationMyeloid leukemiaNeoplasms Second PrimaryHematologyMiddle Agedmedicine.diseaseCombined Modality TherapyTransplantationPostmenopausemedicine.anatomical_structurePremenopauseChemotherapy AdjuvantDoxorubicinMyelodysplastic SyndromesFemaleBone marrowFluorouracilbusinessBone marrow transplantation
researchProduct